Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Name Trading Arrangement, Individual Name Title Trading Arrangement, Individual Title Adoption Date Trading Arrangement Adoption Date Expiration Date Trading Arrangement Expiration Date Arrangement Duration Trading Arrangement Duration Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Amortization of premium (discount) on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in capital Additional Paid in Capital, Common Stock Depreciation Depreciation Amortization of debt issuance costs Amortization of Debt Issuance Costs Amortization of other assets Amortization of Intangible Assets CONSOLIDATED BALANCE SHEETS [Abstract] Basic net loss per share (in dollars per share) Earnings Per Share, Basic Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash, Cash Equivalents and Investments [Abstract] Cash, Cash Equivalents, and Short-Term Investments [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Inventories Increase (Decrease) in Inventories Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common stock, shares authorized to issue (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common stock, $0.001 par value; 300,000,000 shares authorized, 157,908,815 and 144,340,526 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively Current [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred [Abstract] Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk Type [Axis] Concentration Risk Type [Domain] 0.125 percent convertible senior notes, net Convertible Debt, Current Corporate Debt Securities [Member] Corporate Debt Securities [Member] Cost of sales Cost of Goods and Services Sold Cost of Sales Cost of Goods and Service [Policy Text Block] Credit Concentration [Member] Federal Current Federal Tax Expense (Benefit) Foreign Total current income tax expense (benefit) Current Income Tax Expense (Benefit) Total current liabilities Liabilities, Current Current liabilities: Liabilities, Current [Abstract] State Current State and Local Tax Expense (Benefit) Strategic Partner [Member] Customer Concentration Risk [Member] Long-Term Obligations and Commitments Debt Disclosure [Text Block] Outstanding principal balance Face amount Face amount of offering Debt Instrument, Face Amount Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Interest rate Interest rate on convertible senior notes Maturity date Debt Instrument, Name [Domain] Debt Instrument [Axis] Debt Instrument [Line Items] Schedule of Long-term Debt Instruments [Table] 1.75 percent convertible senior notes issuance costs Payments of Debt Issuance Costs Available-for-sale Debt Securities [Member] Debt Securities [Member] Federal Deferred Federal Income Tax Expense (Benefit) Total deferred income tax benefit Deferred Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Deferred Tax Assets [Abstract] Deferred Tax Assets, Gross [Abstract] Deferred revenue Deferred Tax Assets, Deferred Income Total deferred tax assets Deferred Tax Assets, Gross Total net deferred tax assets and liabilities Deferred Tax Assets, Net Net operating loss carryovers Deferred Tax Assets, Operating Loss Carryforwards Other Deferred Tax Assets, Other Tax credits Deferred Tax Assets, Tax Credit Carryforwards Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Valuation allowance Deferred Tax Assets, Valuation Allowance Deferred Tax Liabilities [Abstract] Deferred Tax Liabilities, Gross [Abstract] Right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Other Deferred Tax Liabilities, Other Matching contributions Defined Contribution Plan, Cost Call Spread Derivatives, Policy [Policy Text Block] Diluted net loss per share (in dollars per share) Earnings Per Share, Diluted Basis of Presentation Consolidation, Policy [Policy Text Block] United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Effective rate Effective Income Tax Rate Reconciliation, Percent Reconciliation Between Effective and Statutory Tax Rate Percentage [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Tax rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Net change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Foreign Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Other non-deductible items Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent State income tax net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Capitalized stock-based compensation expense Share-Based Payment Arrangement, Amount Capitalized Stock-based compensation expense, net of amounts capitalized Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] ESPP [Member] Employee Stock [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Stock-Based Compensation [Abstract] Stock-Based Compensation Expense [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Maximum percentage of employee compensation used to purchase shares Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Revenue, Major Customer [Line Items] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Equity Securities [Member] Equity Securities [Member] Fair Value Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Federal [Member] Domestic Tax Jurisdiction [Member] Furniture and Fixtures [Member] Furniture and Fixtures [Member] Non-cash losses related to disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Loss on investments Gain on early retirement of debt Gain (loss) on early retirement of debt Gain (Loss) on Extinguishment of Debt Call Spread [Abstract] General Discussion of Derivative Instruments and Hedging Activities [Abstract] Employee Benefits [Abstract] Retirement Benefits, Description [Abstract] Impairment charge Impairment, Long-Lived Asset, Held-for-Use CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Income Taxes Income Tax Disclosure [Text Block] Interest and penalties on gross unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Income Taxes Income Tax, Policy [Policy Text Block] Reconciliation Between Effective and Statutory Tax Rate [Abstract] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Tax rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Foreign Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Other non-deductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount State income tax net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Income taxes paid (refunds received) Income Taxes Paid, Net Accrued compensation Increase (Decrease) in Other Employee-Related Liabilities Other current and long-term assets Increase (Decrease) in Other Operating Assets Interest expense Interest Expense, Operating and Nonoperating Finished goods Inventory, Finished Goods, Gross Inventories Total inventories Inventory, Net Inventory [Abstract] Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Inventories Inventory, Policy [Policy Text Block] Investment income Investment Income, Net Cash, Cash Equivalents and Investments Investment, Policy [Policy Text Block] Investments [Abstract] Land Improvements [Member] Land Improvements [Member] Undeveloped Land in Carlsbad, California [Member] Land [Member] Leasehold Improvements [Member] Leasehold Improvements [Member] Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Long-term obligations Loans Payable to Bank, Noncurrent Mortgage debt Loans Payable to Bank Less: Current portion included in other current liabilities Long-Term Debt, Current Maturities Thereafter Long-Term Debt, Maturity, after Year Five 2025 Long-Term Debt, Maturity, Year One 2029 Long-Term Debt, Maturity, Year Five 2028 Long-Term Debt, Maturity, Year Four 2027 Long-Term Debt, Maturity, Year Three 2026 Long-Term Debt, Maturity, Year Two Total debt Long-Term Debt, Excluding Current Maturities Total debt and mortgage maturities Long-Term Debt Manufacturing Facility [Member] Debt Maturities [Abstract] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net loss Net Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Net operating loss carryforwards Operating Loss Carryforwards Loss from operations Operating Income (Loss) Revenue Revenues Other current assets Other Assets, Current Other obligations Other Liabilities Other income (expense) Other Nonoperating Income (Expense) Employment Benefits Retirement Benefits [Text Block] Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Proceeds from sale of short-term investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Proceeds from issuance of convertible senior notes Proceeds from issuance of 1.75 percent convertible senior notes Proceeds from issuance of common stock in public offering, net Net proceeds Proceeds from issuance of warrants Proceeds from Issuance of Warrants Proceeds from sale of real estate assets Proceeds from Sale of Property, Plant, and Equipment Cash received from exercise of stock options Proceeds from Stock Options Exercised Property, plant and equipment Property, Plant and Equipment, Gross Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Acquisition of licenses and other assets, net Payments to Acquire Intangible Assets Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Operating Facilities [Abstract] Payments to Acquire Property, Plant, and Equipment [Abstract] Contracts Receivable Receivable [Policy Text Block] Unbilled Royalties Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block] Gross Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Principal payments on mortgage debt Payment of mortgage debt Repayments of Secured Debt Repayment of 0.125 percent convertible senior notes Repurchase of convertible senior notes Repayments of Convertible Debt Research, Development and Patent Expenses Research and Development Expense, Policy [Policy Text Block] Research and development expense Research and Development Expense (Excluding Acquired in Process Cost) Research and Development [Member] Research Tax Credit Carryforward [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Deferred Revenue Revenue [Policy Text Block] Long-Term Obligations Schedule of Long-Term Debt Instruments [Table Text Block] Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Revenue from Collaborative Relationship Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Estimated fair value Debt Securities, Available-for-Sale, Current Segment Information Segment Reporting Disclosure [Text Block] Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Segment Reporting Information [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Selling, general and administrative Selling, General and Administrative Expense Series C Junior Participating Preferred Stock [Member] Stock Plans [Abstract] Share-Based Payment Arrangement, Disclosure [Abstract] Cancelled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted (in shares) Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Non-vested at end of period (in shares) Non-vested at beginning of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Non-vested at beginning of period (in dollars per share) Non-vested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Number of shares authorized for issuance under the Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted average fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Aggregate intrinsic value, outstanding at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at end of period (in shares) Outstanding at beginning of period (in shares) Number of options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding at end of period (in dollars per share) Outstanding at beginning of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Exercisable at end of period (in shares) Number of options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Equity Award [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Short-term investments Short-Term Investments State [Member] State and Local Jurisdiction [Member] CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract] CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] Stock-Based Compensation Expense Share-Based Payment Arrangement [Policy Text Block] Underwriting discounts and commissions and other offering expenses Payments of Stock Issuance Costs Stock Options [Member] Equity Option [Member] Stockholders' equity: Equity, Attributable to Parent [Abstract] Stockholders' Equity [Abstract] Stockholders' Equity Equity [Text Block] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Tax credit carryforwards Tax Credit Carryforward, Amount Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward [Axis] Tax Credit Carryforwards [Abstract] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Table] Total current assets Assets, Current Current assets: Assets, Current [Abstract] Research, Development and Patent Expenses [Abstract] Research and Development Expense [Abstract] Debt Securities Issued by States of the U.S. and Political Subdivisions of the States [Member] US States and Political Subdivisions Debt Securities [Member] Debt Securities Issued by the U.S. Treasury [Member] US Treasury Securities [Member] Ending balance of unrecognized tax benefits Beginning balance of unrecognized tax benefits Unrecognized Tax Benefits Decrease for lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Decrease for prior period tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Increase for current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increase for prior period tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Unrecognized tax benefits that could impact effective tax rate, if recognized Shares used in computing diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Shares used in computing basic net loss per share (in shares) Common Stock [Member] Long-Lived Tangible Asset [Domain] Building, Building Improvements and Building Systems [Member] Building and Building Improvements [Member] R&D expense Research and Development Expense Preferred Stock [Member] Estimated Fair Value [Abstract] Available-for-Sale Securities, Continuous Unrealized Loss Position, Qualitative Disclosure [Abstract] Estimated fair value Debt Securities, Available-for-Sale, Noncurrent Temporarily Impaired Investments [Abstract] Debt Securities, Available-for-Sale [Abstract] Estimated fair value Available-for-sale securities Debt Securities, Available-for-Sale Other Municipal Debt Securities [Member] Other Debt Obligations [Member] Total assets Assets Debt Securities, Trading, and Equity Securities, FV-NI [Table] Other current liabilities Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Income Tax Jurisdiction [Domain] Financial Instruments [Domain] Contract Maturity of Available-for-Sale Securities [Abstract] Available-for-Sale Securities, Debt Maturities [Abstract] Segment Information [Abstract] Segment Reporting Information, Profit (Loss) [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Statement [Table] Convertible notes Notes Payable, Fair Value Disclosure Increase in valuation allowance SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) ASSETS Assets [Abstract] Statement [Line Items] Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Abstract] Quoted Prices in Active Markets (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Ownership Interests in Private and Public Companies [Abstract] Investments, All Other Investments [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Fourth Quarter Financial Data (Unaudited) Quarterly Financial Information [Text Block] Payment to acquire building Class of Stock [Domain] Fourth Quarter Financial Data (Unaudited) [Abstract] Selected Quarterly Financial Information [Abstract] Purchases of short-term investments Payments to Acquire Debt Securities, Available-for-Sale Cash and Cash Equivalents [Member] Federal [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Less: Debt issuance costs Unamortized debt issuance costs Debt Issuance Costs, Net Convertible senior notes, net Convertible Debt, Noncurrent Convertible senior notes Convertible Debt Deposits and other assets Other Assets, Noncurrent Basic and Diluted Net Loss Per Share [Abstract] Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Basic and Diluted Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Debt and Equity Securities, FV-NI [Line Items] Debt Securities, Available-for-Sale [Line Items] Class of Stock [Axis] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Property, Plant and Equipment [Table] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Currency translation adjustment Foreign currency translation Long-Lived Tangible Asset [Axis] Property, Plant and Equipment [Line Items] Common shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Convertible Debt Debt, Policy [Policy Text Block] Total stockholders' equity Balance Balance Equity, Attributable to Parent Net change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment Total income tax expense (benefit) Income tax benefit (expense) Income Tax Expense (Benefit) Common Stock [Abstract] Preferred Stock [Abstract] Debt Securities Issued by U.S. Government Agencies [Member] US Government Agencies Debt Securities [Member] Convertible Debt [Abstract] Long-Term Debt, by Type, Current and Noncurrent [Abstract] Contracts Receivables [Member] Accounts Receivable [Member] Equity Components [Axis] Additional Paid in Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated Other Comprehensive Loss [Member] Equity Component [Domain] Employee Stock Options [Member] Stock Options [Member] Employee Stock Option [Member] Loss on investments Realized Investment Gains (Losses) Cancelled/forfeited/expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Issuance of public common stock, net Stock Issued During Period, Value, New Issues Issuance of public common stock, net (in shares) Stock Issued During Period, Shares, New Issues Issuance of common stock in connection with employee stock plans, net (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Shares purchased and issued under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Segments [Axis] Collaborative Arrangements and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Expenses: Costs and Expenses [Abstract] Total operating expenses Operating expenses Costs and Expenses Supplemental disclosures of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Number of Shares [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Average Remaining Contractual Term, Aggregate Intrinsic Value and Other [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Number of Shares [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Weighted-Average Assumptions [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Balance (in shares) Balance (in shares) Shares, Issued Income taxes payable Accrued Income Taxes, Current Contracts Receivable [Abstract] Contracts Receivable [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Stock by Class [Table] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Convertible Debt [Abstract] Convertible Notes Payable [Abstract] Long-Term Obligations [Abstract] Less: Fixed and determinable interest Interest Payable Accounts payable Accounts Payable, Current Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Accrued compensation Employee-related Liabilities, Current Other miscellaneous expenses Other Accrued Liabilities, Current Accrued Liabilities [Abstract] Accrued Liabilities, Current [Abstract] Unrealized gains (losses) on investments, net of tax Change in unrealized gains (losses), net of tax Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Non-cash losses related to other assets Impairment of Intangible Assets, Finite-Lived Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases Proceeds from issuance of common stock through equity plans, net Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Purchase of note hedges Payments for Hedge, Financing Activities Loss before income tax benefit (expense) Pre-tax loss Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Total Assets, Fair Value Disclosure Segments [Domain] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Recurring Basis [Member] Fair Value, Recurring [Member] Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options Payment, Tax Withholding, Share-Based Payment Arrangement Income taxes Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation TEGSEDI and WAYLIVRA Revenue, Net [Member] Product [Member] Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Organization and Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization and Significant Accounting Policies [Abstract] Available-for-sale Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation of Statutory to Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Loss Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Inventories Schedule of Inventory, Current [Table Text Block] Legal Proceedings [Abstract] Legal Proceedings Legal Matters and Contingencies [Text Block] Income Taxes [Abstract] Fair Value Measurements [Abstract] Convertible Debt [Abstract] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Employment Benefits [Abstract] Fourth Quarter Financial Data (Unaudited) Quarterly Financial Information [Table Text Block] Weighted-Average Assumptions for ESPP Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-Average Assumptions for Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fourth Quarter Financial Data (Unaudited) [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Summary of Investments Unrealized Gain (Loss) on Investments [Table Text Block] Restricted Stock Units [Member] RSUs [Member] Restricted Stock Units (RSUs) [Member] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Segment Information [Abstract] Supplemental Financial Data Supplemental Balance Sheet Disclosures [Text Block] Accrued liabilities and other current liabilities Increase (Decrease) in Other Current Liabilities Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Income Tax Jurisdiction [Axis] Issuance of common stock in connection with employee stock plans, net Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture Number of shares issued for stock option exercises, vesting of restricted stock units, and ESPP purchases (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Aggregate intrinsic value, exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Contract Maturity of Available-for-Sale Securities Investments Classified by Contractual Maturity Date [Table Text Block] Number of awards outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Weighted Average Grant Date Fair Value per Share [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Cancelled/forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unrecognized compensation cost related to non-vested stock options Unrecognized compensation cost related to non-vested units Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Financial Instrument [Axis] Weighted Average Exercise Price Per Share [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cancelled/forfeited/expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price PRSUs [Member] Performance Restricted Stock Units [Member] Performance Shares [Member] Unrecognized Compensation Expense [Abstract] Balance Sheet Location [Axis] Plan Name [Axis] Plan Name [Domain] Award Type [Axis] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Number of additional shares reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Recent Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Intangible and capital assets Deferred Tax Assets, Goodwill and Intangible Assets Principal amount repurchased Estimated useful life Property, Plant and Equipment, Useful Life Average remaining contractual term, outstanding at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Average remaining contractual term, exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Expected life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Period before options are exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Weighted average period for recognition Weighted average period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Percentage of fair market value used to determine purchase price of stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Number of operating segments Number of Operating Segments Other Current Assets [Member] Selling, General and Administrative [Member] Selling, General and Administrative Expenses [Member] Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Concentration percentage Conversion price per share (in dollars per share) Balance Sheet Location [Domain] Cost of Sales [Member] Cost of Sales [Member] Investments Employee contribution limit per calendar year Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Fair Value Measurements [Abstract] Fair Value, Net Asset (Liability) [Abstract] Gain (loss) on sale of real estate assets Gain on sale of real estate assets Share price (in dollars per share) Shares Issued, Price Per Share Convertible Senior Notes Convertible Debt [Table Text Block] Vesting [Axis] Vesting [Domain] Award term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Liability Related to Sale of Future Royalties Other Noncurrent Liabilities [Table Text Block] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Award Date [Axis] Award Date [Domain] Performance Restricted Stock Unit Activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Total stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Losses [Abstract] Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] Other Income [Member] Other Nonoperating Income (Expense) [Member] One Year from Date of Grant [Member] One-Year Period [Member] Two-Year Period [Member] Three-Year Period [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] California [Member] California Franchise Tax Board [Member] Defined Contribution Plan [Table] Defined Contribution Plan Disclosure [Line Items] Available-for-sale Debt Securities [Abstract] Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Revenues [Abstract] Disaggregation of Revenue [Abstract] Revenues Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue recognized from amounts in beginning deferred revenue balance Contract with Customer, Liability, Revenue Recognized Contracts Receivable [Abstract] Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract] Contracts receivable Contract with Customer, Asset, after Allowance for Credit Loss, Current Revenues [Abstract] Revenue: Revenues Revenue from Contract with Customer [Text Block] Operating Leases [Abstract] Lessee Disclosure [Abstract] Deferred Revenue [Abstract] Contract with Customer, Liability [Abstract] Current portion of deferred contract revenue Contract with Customer, Liability, Current Long-term deferred contract revenue Contract with Customer, Liability, Noncurrent Deferred contract revenue Contract with Customer, Liability Right-of-use assets Right-of-use operating lease assets Future Payments for Operating Lease Liabilities [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue [Member] Revenue from Contract with Customer Benchmark [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Effects of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents at end of year Cash and cash equivalents at beginning of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Operating lease cash payments Operating Lease, Payments Right-of-use assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Lease payments to be made over initial term of lease Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five 2025 Lessee, Operating Lease, Liability, to be Paid, Year One 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Future Payments for Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Rent expense Lease payments to be received over term of sublease Lessor, Operating Lease, Payment to be Received Loss (gain) on sale of real estate assets Sale and Leaseback Transaction, Gain (Loss), Net Operating lease liabilities Lease liabilities Operating Lease, Liability Less: Current portion (included in other current liabilities) Operating Lease, Liability, Current Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Long-term lease liabilities Total long-term lease liabilities Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Leases Lessee, Leases [Policy Text Block] Long-Term Obligations and Commitments Lessee, Operating Leases [Text Block] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Initial term of lease Lessee, Operating Lease, Term of Contract Term of lease extension Lessee, Operating Lease, Renewal Term Term of sublease Lessor, Operating Lease, Term of Contract Less than 12 months of temporary impairment Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss More than 12 months of temporary impairment Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Available-for-sale Debt Securities with Maturity of One Year or Less [Abstract] Debt Securities, Current [Abstract] Available-for-sale Debt Securities with Maturity of More Than One Year [Abstract] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Contracts receivable Increase (Decrease) in Contract with Customer, Asset Deferred contract revenue Increase (Decrease) in Contract with Customer, Liability Debt Securities, Available-for-Sale [Table] Number of investments Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Less than 12 months of temporary impairment Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months More than 12 months of temporary impairment Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Total temporary impairment Debt Securities, Available-for-Sale, Unrealized Loss Position Total temporary impairment Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Temporarily Impaired Investments Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Equity securities Estimated fair value Equity Securities, FV-NI, Current Amortized cost Equity Securities, FV-NI, Cost Unrealized loss on equity securities Equity Securities, FV-NI, Unrealized Loss Grantee Status [Axis] Grantee Status [Domain] Employees [Member] Share-Based Payment Arrangement, Employee [Member] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Current Amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Amortization of right-of-use operating lease assets Operating Lease, Right-of-Use Asset, Periodic Reduction Equity Securities [Abstract] Equity Securities, FV-NI [Abstract] Impairment, Long-Lived Asset, Held-for-Use, Statement of Income [Extensible Enumeration] Foreign-derived intangible income benefit Effective Income Tax Rate Reconciliation, FDII, Percent Foreign-derived intangible income benefit Effective Income Tax Rate Reconciliation, FDII, Amount Segment Reporting, Other Segment Item, Composition, Description Other segment items Segment Reporting, Other Segment Item, Amount Customer [Domain] Executive Officers [Member] Executive Officer [Member] Customer [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Debt Maturity Schedules Contractual Obligation, Fiscal Year Maturity [Table Text Block] Product and Service [Domain] Product and Service [Axis] Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Cover [Abstract] Document Type Document Annual Report Document Transition Report Document Financial Statement Error Correction [Flag] Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Firm ID Auditor Location Collaborative Arrangements and Licensing Agreements [Abstract] 1.75 percent convertible senior notes due June 2028. Convertible Senior Notes 1.75 Percent [Member] 1.75% Notes [Member] 1.75 Percent Convertible Senior Notes [Member] Amount of long-term debt, lease obligations and other obligations., classified as current. Long-term Obligations, Current Less: current portion Amount of long-term debt, lease obligations and other obligations, classified as noncurrent. Long-term Obligations, Noncurrent Total Long-Term Obligations Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Liability Related to Sale of Future Royalties, Net Liability related to sale of future royalties Net liability related to sale of future royalties Liability related to sale of future royalties, net Including the current and noncurrent portions, amount of long-term debt, lease obligations and other obligations. Long-term Obligations Total 0.125 percent convertible senior notes due December 2024. Convertible Senior Notes 0.125 Percent [Member] 0.125% Notes [Member] 0.125 Percent Convertible Senior Notes [Member] 0 percent convertible senior notes due April 2026. Convertible Senior Notes 0 Percent [Member] 0 Percent Convertible Senior Notes [Member] 0% Notes [Member] Supplemental Financial Data [Abstract] Period of time in which the lessor provides free rent under operating lease to the lessee, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lessor, Operating Lease, Period of Free Rent Period of free rent under sublease Another office space located in Boston, Massachusetts leased under non-cancelable operating lease entered into in September 2021. Another Office Space in Boston [Member] Sublease of office space located in Boston, Massachusetts leased under non-cancelable sublease operating lease entered into in January 2022. Subleased Office Space in Boston [Member] Number of lots of undeveloped land adjacent to the Company's headquarters transferred to real estate investor. Number of lots of undeveloped land transferred to real estate investor Number of lots of undeveloped land transferred to real estate investor Additional office space in Carlsbad, California leased under non-cancelable operating lease. Carlsbad Office Space [Member] Carlsbad Office Space [Member] Period of time in which the rent is free under operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lessee, Operating Lease, Period of Free Rent Period of free rent under lease Warehouse space in Carlsbad, California leased under non-cancelable operating lease. Carlsbad Warehouse Space [Member] Carlsbad Warehouse Space [Member] The number of options to extend the lease under the lessor's operating lease. Lessor, Operating Lease, Number of options to extend lease Number of options to extend sublease Headquarters location located in Carlsbad, California. Headquarters Location in Carlsbad, California [Member] Headquarters Location in Carlsbad, California [Member] Office space located in Boston, Massachusetts leased under non-cancelable operating lease entered into in the second quarter of 2018.. Boston Office Space [Member] Boston Office Space [Member] Office and laboratory space in a facility adjacent to the Company's manufacturing facility located in Carlsbad, California leased under non-cancelable operating lease. Carlsbad Facility [Member] Carlsbad Facility [Member] The number of options to extend the lease under the lessee's operating lease. Lessee, Operating Lease, Number of options to extend lease Number of options to extend lease Development chemistry and manufacturing facility located in Oceanside, California. Development Chemistry and Manufacturing Facility in Oceanside, California [Member] Development Chemistry and Manufacturing Facility in Oceanside, California [Member] 0.125 percent convertible senior notes due December 2024 that were issued under subscription agreements in December 2019. Convertible Senior Notes 0.125 Percent, Issued under Subscription Agreements [Member] 0.125% Notes Issued under Subscription Agreements [Member] Portion of total proceeds from the issuance of 0 percent convertible senior notes due April 2026 used to pay the remaining principal balance of the 1 percent convertible senior notes due November 2021. Convertible Senior Notes 0 Percent, Used to Pay Remaining Balance of 1 Percent Convertible Senior Notes [Member] 0% Notes [Member] Portion of total proceeds from the issuance of 1.75 percent convertible senior notes due June 2028 used to repurchase a portion of the 0.125 percent convertible senior notes due December 2024. Convertible Senior Notes 1.75 Percent, Used to Repurchase 0.125 Percent Convertible Senior Notes [Member] 1.75% Notes [Member] 0.125 percent convertible senior notes due December 2024 that were issued in exchange for 1 percent notes in December 2019. Convertible Senior Notes 0.125 Percent, Issued in Exchange for 1 Percent Notes [Member] 0.125% Notes Issued in Exchange for 1% Notes [Member] Includes 0% convertible senior notes due April 2026, 0.125% convertible senior notes due December 2024, and 1% convertible senior notes due November 2021. Convertible Senior Notes [Member] Convertible Senior Notes [Member] The number of shares of common stock subject to conversion if the debt was converted to equity. Debt Instrument, Convertible, Shares Subject to Conversion Total shares of common stock subject to conversion (in shares) The computed conversion price per share of the debt instrument based on the the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction. Debt Instrument, Convertible, Conversion Price including call spread Effective conversion price per share with call spread (in dollars per share) The net cash outflow from payments for hedge transactions and proceeds from the issuance of warrants. The call spread transaction was entered into to minimize the impact of potential economic dilution upon conversion of the 0.125% notes issued. Call Spread Cost of call spread The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes. Debt Instrument, Convertible, Percentage of principal amount used as purchase price upon occurrence of fundamental change Percentage of principal amount used as purchase price upon occurrence of fundamental change 1 percent convertible senior notes due November 2021. Convertible Senior Notes 1 Percent [Member] 1% Notes [Member] Royalty revenues from the sale of WAINUA (eplontersen). WAINUA Royalties [Member] WAINUA Royalties [Member] Amount of interest expense using the effective interest rate method and amortization of issuance costs related to the sale of future royalties. Interest Expense and Amortization of Issuance Costs Related to Sale of Future Royalties Interest expense related to sale of future royalties The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense. Research, Development and Patent Expense Research, development and patent Joint development revenue for WAINUA (eplontersen). WAINUA Joint Development Revenue [Member] WAINUA Joint Development Revenue [Member] Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA.. Commercial [Member] Commercial Revenue [Member] Royalty revenues from the sale of SPINRAZA (nusinersen). SPINRAZA Royalties [Member] SPINRAZA Royalties [Member] Revenue from research and development services. Research and Development Revenue [Member] Research and Development Revenue [Member] Revenue from research and development services performed under a collaborative agreement. Collaborative Agreement Revenue [Member] Collaborative Agreement Revenue [Member] Revenue from the sale of other medicines commercially as well as licensing and royalty revenue from other medicines, including TEGSEDI and WAYLIVRA. Other Commercial [Member] Other Commercial Revenue [Member] Three significant corporate partners and leading global pharmaceutical companies that are working alongside the Company to develop the Company's drugs, advance the Company's technology, and prepare to commercialize and sell the Company's drugs under collaborative arrangement and licensing agreements. Three Significant Customers [Member] Three Significant Customers [Member] Number of quarters after billing when payment is received from the Company's partner or customer. Number of quarters after billing when payment is received Number of quarters after billing when payment is received The number of significant customers with which the Company does business. Number of Significant Customers Number of significant customers One significant corporate partner and leading global pharmaceutical company that is working alongside the Company to develop the Company's medicines, advance the Company's technology, and prepare to commercialize and sell the Company's medicines under collaborative arrangement and licensing agreements. One Significant Customer [Member] One Significant Customer [Member] Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development expenses. Deferred Tax Assets, Capitalized Research and Development Expenses Capitalized research and development expenses Amount before allocation of valuation allowances of deferred tax asset attributable to the sale of future royalties. Deferred Tax Assets, Sale of Future Royalties Sale of future royalties Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from financing arrangements. Deferred Tax Assets, Financing Arrangements Convertible debt Represents the net amount of deferred tax assets (before reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. Deferred Tax Assets (Liabilities), Net, before Valuation Allowance Net deferred tax asset Amount before allocation of valuation allowances of deferred tax asset attributable to leasing arrangements. Deferred Tax Assets, Leasing Arrangements Long-term lease liabilities Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any "covered employee" of the corporation under Section 162(m) of the Tax Act. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent Non-deductible compensation Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any "covered employee" of the corporation under Section 162(m) of the Tax Act. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Amount Non-deductible compensation Royalty Revenue Monetization [Abstract] Royalty Revenue Monetization [Abstract] The maximum amount of annual sales on which royalty payments are paid under the royalty purchase agreement. Maximum amount of annual sales on which royalty payments are paid Maximum amount of annual sales on which royalty payments are paid Nusinersen, marketed as Spinraza, is a medicine used in treating spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. SPINRAZA [Member] SPINRAZA [Member] The percentage of royalty payments paid on annual sales of medicine. Percentage of royalty payments paid on annual sales of medicine Percentage of royalty payments paid to Royalty Pharma on annual sales of medicine Percentage of royalty payments paid on annual sales of medicine The maximum amount of payments receivable for additional milestones under the royalty purchase agreement. Maximum amount of payments receivable for additional milestones Maximum royalty payments under the royalty purchase agreement made before royalty interest reverts back to the Company. Maximum royalty payments made before royalty interest reverts back Maximum royalty payments made before royalty interest reverts back The amount of upfront payments received during the period under the royalty purchase agreement. Upfront royalty payment received Upfront payment received Pelacarsen, also known as IONIS-APO(a)-L, AKCEA-APO(a)-L, and TQJ230, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver in patients suffering from high levels of the lipoprotein Lp(a). Pelacarsen [Member] Pelacarsen [Member] In January 2023, the Company entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of future SPINRAZA and pelacarsen royalties the Company is entitled to under arrangements with Biogen and Novartis, respectively. Royalty Purchase Agreement [Member] Royalty Purchase Agreement [Member] The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements. Payments for Transaction Costs Related to Sale of Future Royalties Payments of transaction costs related to sale of future royalties Transaction costs Issuance costs related to sale of future royalties Amount of amortization expense attributable to the sale of future royalties. Amortization of Issuance Costs Related to Sale of Future Royalties Amortization of issuance costs related to sale of future royalties The cash inflow from the sale of future royalties under a royalty purchase agreement. Proceeds from Sale of Future Royalties Proceeds from sale of future royalties The amount of royalty payments made during the period under a royalty purchase agreement. Royalty Payments Non-cash royalty revenue related to sale of royalties Royalty payments to Royalty Pharma Amount of interest expense using the effective interest rate method related to the sale of future royalties. Interest Expense Related to Sale of Future Royalties Non-cash interest related to sale of future royalties Interest expense related to sale of future royalties Measurement period for alternative payout mechanism, or the Alternative Calculation, included in equity-based award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Measurement Period for Alternative Payout Mechanism Measurement period for Alternative Calculation Term of an alternative three-year payout mechanism, or the Alternative Calculation, included in equity-based award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Term of Alternative Payout Mechanism Term of Alternative Calculation Awards granted at initial appointment to the board of directors. Granted at Initial Appointment [Member] Granted at Initial Appointment [Member] Awards granted in 2020 through 2022. Granted 2020 through 2022 [Member] Granted 2020 through 2022 [Member] Awards granted in 2024 and 2023. Granted in 2024 and 2023 [Member] Granted in 2024 and 2023 [Member] Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires. Share-based Payment Arrangement, Board of Directors [Member] Board of Directors [Member] Awards granted prior to June 2020. Granted Prior to June 2020 [Member] Granted Prior to June 2020 [Member] Awards granted after June 2020. Granted After June 2020 [Member] Granted After June 2020 [Member] Number of separate performance periods under share-based payment arrangement. Share-based Compensation Arrangement by Share-based Payment Award, Number of Performance Periods Number of performance periods Number of units guaranteed to vest under share-based payment arrangement. Share-based Compensation Arrangement by Share-based Payment Award, Number of units guaranteed to vest Number of units guaranteed to vest (in shares) Percentage of units guaranteed to vest under share-based payment arrangement. Share-based Compensation Arrangement by Share-based Payment Award, Percentage of units guaranteed to vest Percentage of units guaranteed to vest Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time granted on January 1, 2022 and thereafter. Share-based Payment Arrangement, Options Granted on January 1, 2022 and Thereafter [Member] Stock Options Granted on January 1, 2022 and Thereafter [Member] Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time granted prior to January 1, 2022. Share-based Payment Arrangement, Options Granted Prior to January 1, 2022 [Member] Stock Options Granted Prior to January 1, 2022 [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications and internally developed software for long-term internal use. Includes other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services, such as laboratory, manufacturing and other equipment. Equipment and Computer Software [Member] Computer Software, Laboratory, Manufacturing and Other Equipment [Member] Period of time to make only payments of interest on the mortgage loan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period to make interest only payments on mortgage loan Period to make interest only payments on mortgage loan Loan agreement with UBS AG entered into on July 18, 2017 to finance the purchase of the Company's research and development facility. Manufacturing Facility Mortgage [Member] Manufacturing Facility Mortgage [Member] Loan agreement with UBS AG entered into on July 18, 2017 to finance the purchase of the Company's primary research and development (R&D) facility. Primary Research and Development Facility Mortgage [Member] Primary R&D Facility Mortgage [Member] The number of purchased facilities financed with mortgage debt. Number of purchased facilities financed with mortgage debt Number of purchased facilities financed with mortgage debt Two loan agreements with UBS AG entered into on July 18, 2017 to finance the purchase of the Company's research and development and manufacturing facilities. Long-term Mortgage Debt [Member] Long-term Mortgage Debt [Member] Facility constructed for the entity's primary research and development activities under a lease agreement with an affiliate of BioMed Realty, L.P. Primary Research and Development Facility [Member] Primary R&D Facility [Member] New research and development (R&D) facility in Carlsbad, California composed of R&D and office space. New Research and Development Facility in Carlsbad, CA [Member] New R&D Facility in Carlsbad, CA [Member] Number of purchase and sale agreements entered into with a real estate investor. Number of purchase and sale agreements entered into with real estate investor Number of purchase and sale agreements entered into with real estate investor An arrangement whereby a member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as a form of compensation. Board of Director Stock Option [Member] Board of Director Stock Options [Member] Awards issued after December 31, 2021. Issued after December 31, 2021 [Member] Issued after December 31, 2021 [Member] Represents the stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to employees, directors, and consultants. Equity Incentive Plan 2011 [Member] 2011 Equity Incentive Plan [Member] In December 2020, the Company amended and restated the Akcea 2015 Equity Incentive Plan, including renaming the plan as the Ionis Pharmaceuticals, Inc. 2020 Equity Incentive Plan, or 2020 Plan. The 2020 Plan provided for the issuance of up to 2.6 million shares of Common Stock to employees, directors and consultants who were employees of Akcea prior to the Akcea Acquisition. Equity Incentive Plan 2020 [Member] 2020 Equity Incentive Plan [Member] The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Fair Value Weighted-average fair value of options exercised (in dollars per share) The cash inflow from the transfer of legal ownership of two lots of undeveloped land to a real estate investor. Proceeds from Real Estate Transaction Proceeds from real estate transaction Future cash outflow to pay for purchases of fixed assets and patents that have occurred. Capital and Patent Expenditures Incurred but Not Yet Paid Amounts accrued for capital and patent expenditures The number of additional targets to be researched, developed and commercialized under the collaboration agreement upon achievement of certain development milestones. Number of additional targets to be researched, developed and commercialized Number of additional targets to be researched, developed and commercialized The number of targets to be researched, developed and commercialized under the collaboration agreement. Number of targets to be researched, developed and commercialized Number of targets to be researched, developed and commercialized Collaborative Arrangement and Licensing Agreement [Abstract] Amount of cash outflow to license technology under a collaboration and license agreement. Payment to license technology Payment to license technology License agreement entered into with Metagenomi in November 2022 to research, develop and commercialize investigational medicines for up to eight potential targets using gene editing technologies. Metagenomi License Agreement [Member] Metagenomi [Member] Disclosure of inventory accounting policy for liability related to sale of future royalties. Liability Related to Sale of Future Royalties, Policy [Policy Text Block] Liability Related to Sale of Future Royalties Disclosure of accounting policy for capitalization of materials used in manufacturing medicines in clinical development programs. Capitalized Materials, Policy [Policy Text Block] Capitalized Materials Disclosure of accounting policy for estimating accrued liabilities, including the liability for preclinical and clinical development costs. Accrued Liabilities, Policy [Policy Text Block] Accrued Liabilities Primary financial statement caption encompassing research, development and patent expenses. Research, Development and Patent [Member] Research, Development and Patent [Member] The number of executive officers terminated by the Company during the period that begins three months before and ends twelve months following a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers Number of executive officers terminated before change in control when vesting will accelerate for executive officers Number of executive officers terminated before change in control when vesting will accelerate for executive officers Period of time before a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period before change in control when vesting will accelerate for executive officers Period before change in control when vesting will accelerate for executive officers Period of time after a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period after change in control when vesting will accelerate for executive officers Period after change in control when vesting will accelerate for executive officers Represents the holding period from the date of purchase for stock purchased under the plan. Share-based Compensation Arrangement by Share-based Payment Award, Holding Period Holding period for purchased stock Weighted average sales price of shares purchased through an employee stock purchase plan. Employee Stock Purchase Plan, Weighted Average Sales Price of Shares Purchased Weighted average purchase price (in dollars per share) The number of shares available for purchase under an employee stock purchase plan. Employee Stock Purchase Plan, Shares Available for Purchase Shares available for purchase under ESPP (in shares) Represents the 2002 Non-Employee Directors Stock Option Plan, which provided for the issuance of stock options to the entity's non-employee directors for the purchase of common stock. Nonemployee Directors' Stock Option Plan 2002 [Member] 2002 Non-Employee Directors' Stock Option Plan [Member] Represents the 1989 Stock Option Plan, which provides the issuance of non-qualified and incentive stock options for the purchase of common stock to the entity's employees, directors and consultants. Stock Option Plan 1989 [Member] 1989 Stock Option Plan [Member] Represents the 2009 Employee Stock Purchase Plan, as amended and restated, which permits full-time employees to purchase common stock through payroll deductions at a percentage of the fair market value. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Increase (decrease) in the number of shares in the "fungible" share reserve for each share issued pursuant to full value award. Increase (decrease) in fungible share reserve for each share issued pursuant to full value award Reduction in fungible share reserve for each share issued pursuant to full value award (n shares) Increase (decrease) in the number of shares in the "fungible" share reserve for each share of common stock returning from a full value award. Increase (decrease) in fungible share reserve for each share returning from full value award Increase in fungible share reserve for each share returning from a full value award (in shares) Tabular disclosure of information on lessee's operating leases, including carrying value of right-of-use assets and lease liabilities, weighted-average remaining term and weighted-average discount rate. Lessee, Operating Lease Information [Table Text Block] Amounts Related to Operating Leases Disclosure of information about income taxes. Convertible Notes Disclosure [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Convertible Notes Disclosure [Line Items] Convertible Debt [Abstract] Tabular disclosure of the useful lives of physical assets used in the normal conduct of business and not intended for resale. Property, Plant and Equipment Useful Lives [Table Text Block] Property, Plant and Equipment Includes charges for amortization and write-downs of capitalized patent costs as well as legal fees for patent litigation and patent defense. Patent Expenses Patent expenses Total of (1) unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Debt Securities, Available-for-sale and Equity Securities, FV-NI, Gross Unrealized Gain Gross unrealized gains Total of (1) amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Debt Securities, Available-for-sale and Equity Securities, FV-NI, Cost Amortized cost Total of (1) unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Debt Securities, Available-for-sale and Equity Securities, FV-NI, Gross Unrealized Loss Gross unrealized losses Total of (1) investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Debt Securities, Available-for-sale and Equity Securities, FV-NI Estimated fair value Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method. Number of Privately-Held Companies in which Entity has Equity Investment Number of privately held companies in which there is an equity ownership interest of less than 20% Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value. Number of Publicly-Held Companies in which Entity has Equity Investment Number of publicly held companies in which there is an equity ownership interest of less than 20% Ownership interest or right to acquire or dispose of ownership interest in publicly traded corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants. Equity Securities, Publicly Traded Companies [Member] Publicly Traded Equity Securities [Member] Ownership interest or right to acquire or dispose of ownership interest in private corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants. Equity Securities, Private Companies [Member] Privately Held Equity Securities [Member] Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current Gross unrealized losses Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Current Gross unrealized gains Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Noncurrent Gross unrealized gains Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent Gross unrealized losses Accumulated amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Equity Securities, FV-NI, Accumulated Gross Unrealized Gain Gross unrealized gains Accumulated amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Equity Securities, FV-NI, Accumulated Gross Unrealized Loss Gross unrealized losses The maximum contract maturity period for the second range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Maximum contract maturity period, range 2 Maximum contract maturity period, range 2 The maximum contract maturity period for the first range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Maximum contract maturity period, range 1 Maximum contract maturity period, range 1 The maximum contract maturity period for the third range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Maximum contract maturity period, range 3 Maximum contract maturity period, range 3 The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date. Available-for-sale Securities, Debt Maturities, after Two Through Three and One Half Years, Percentage After two years but within three and a half years The percentage of available-for-sale debt securities that mature within two years of the balance sheet date. Available-for-sale Securities, Debt Maturities, within Two Years, Percentage Percentage of available-for-sale securities with a maturity of less than two years The aggregate percentage of all available-for-sale debt securities, regardless of maturity. Available-for-sale Securities, Debt Maturities, Total, Percentage Total The percentage of available-for-sale debt securities that mature within one year of the balance sheet date. Available-for-sale Securities, Debt Maturities, within One Year, Percentage One year or less The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date. Available-for-sale Securities, Debt Maturities, after One Through Two Years, Percentage After one year but within two years Collaboration agreement entered into with AstraZeneca PLC in July 2015 to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney and renal diseases. AstraZeneca Collaboration, Cardiovascular, Renal and Metabolic Diseases [Member] Cardiovascular, Renal and Metabolic Diseases [Member] Collaboration agreement entered into with AstraZeneca PLC in December 2021 to develop and commercialize WAINUA. WAINUA (eplontersen), formerly known as IONIS-TTR-L and AKCEA-TTR-L, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease. AstraZeneca Collaboration, WAINUA [Member] WAINUA [Member] WAINUA (Eplontersen) Collaboration with AstraZeneca [Member] ION826 is a medicine designed for the treatment of heart failure. Ion826 [Member] ION826 [Member] Number of outstanding convertible notes. Debt Instrument, Number of convertible notes Number of outstanding convertible notes Collaboration agreements entered into with Otsuka Pharmaceutical Co., Ltd. Otsuka Collaborations [Member] Otsuka [Member] Represents activity related to Alnylam Pharmaceuticals, Inc.. Alnylam Pharmaceuticals, Inc. [Member] Alnylam [Member] Disclosure of information about collaborative arrangements and non-collaborative arrangement transactions. Collaborative Arrangements and Non-collaborative Arrangement Transactions Disclosure [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Collaborative Arrangements and Non-collaborative Arrangement Transactions Disclosure [Line Items] Collaborative Arrangements and Licensing Agreements [Abstract] Collaboration agreement entered into with Novartis International AG (Novartis) in January 2017 to develop and commercialize pelacarsen and olezarsen. Novartis Collaboration [Member] Novartis [Member] Collaboration agreement entered into with GlaxoSmithKline (GSK) in March 2010 to discover and develop new medicines against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Glaxo Smith Kline Collaboration [Member] GSK [Member] Collaboration agreements entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche. Roche Collaborations [Member] Roche [Member] Collaboration agreements entered into with Biogen Inc. Biogen Collaborations [Member] Biogen [Member] Collaboration agreements entered into with AstraZeneca PLC. AstraZeneca Collaborations [Member] AstraZeneca [Member] The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration. Revenue from Contract with Customer, Transaction Price Transaction price The number of separate performance obligations under the collaboration agreement. Revenue from Contract with Customer, Number of separate performance obligations Number of separate performance obligations The maximum amount of milestone payments to be received for each medicine that is successfully developed over the term of the collaboration. Maximum amount of milestone payments per medicine over term of collaboration Maximum amount of milestone payments for each additional medicine successfully developed over term of collaboration Royalty percentage received on the net sales of a medicine by a collaboration partner under the collaboration agreement. Royalty percentage received on net sales of medicine Royalty percentage received on net sales of medicine Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period. Cumulative payments received Cumulative payments received Number of early-stage programs to be developed for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD). Number of early-stage programs The maximum amount of regulatory milestone payments to be received over the term of the collaboration. Maximum amount of regulatory milestone payments over term of collaboration Maximum amount of regulatory milestone payments over term of collaboration The maximum amount of upfront payments to be received over the term of the collaboration. Maximum amount of upfront payments over term of collaboration Maximum amount of upfront payments over term of collaboration The maximum amount of payments the Company is eligible to receive over the term of the collaboration. Maximum amount of payments receivable over term of collaboration Maximum amount of payments receivable over term of collaboration The maximum amount of development milestone payments to be received over the term of the collaboration. Maximum amount of development milestone payments over term of collaboration Maximum amount of development milestone payments over term of collaboration The maximum amount of license fees to be received over the term of the collaboration. Maximum amount of license fees over term of collaboration Maximum amount of license fees over term of collaboration The next payment to be achieved under the collaboration agreement. Next payment to be achieved Next payment to be achieved The maximum amount of sales milestone payments to be received over the term of the collaboration. Maximum amount of sales milestone payments over term of collaboration Maximum amount of sales milestone payments over term of collaboration Research and development (R&D) services for the investigational medicine for Huntington's Disease (HD). Research and Development Services for Investigational Medicine for Huntington's Disease [Member] R&D Services for Investigational Medicine for HD [Member] Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation. Cumulative payments included in transaction price for performance obligation Cumulative payments included in transaction price for performance obligation Research and development (R&D) services for the investigational medicine for Alzheimer's Disease (AD). Research and Development Services for Investigational Medicine for Alzheimer's Disease [Member] R&D Services for Investigational Medicine for AD [Member] Collaboration agreement entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, in September 2023 to develop two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD). Roche Collaboration, RNA-targeted Programs for AD and HD [Member] RNA-targeted Programs for AD and HD [Member] The amount of upfront payments received during the period under the collaboration agreement. Upfront payment received Upfront payment received Collaboration agreement entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, in October 2018 to develop IONIS-FB-L for the treatment of complement-mediated diseases. Roche Collaboration, Ionis-Fb-L for Complement-Mediated Diseases [Member] Sefaxersen [Member] Collaboration agreement entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, in April 2013 to develop treatments for Huntington's disease, or HD, based on the Company's antisense technology. Roche Collaboration, Huntington's Disease [Member] HD [Member] IONIS-MAPT is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain, for the treatment of Alzheimer's disease. Ionis-Mapt [Member] IONIS-MAPT [Member] Research and development revenue from QALSODY. QALSODY Research and Development [Member] QALSODY R&D Revenue [Member] Royalty revenues from the sale of QALSODY. QALSODY Royalties [Member] QALSODY Royalties [Member] ION306 is an antisense oligonucleotide or ASO that is designed to boost production of the survival motor neuron protein, known as SMN. Ion306 [Member] ION306 [Member] The maximum amount of development milestone payments to be received for each medicine that achieves marketing approval over the term of the collaboration. Maximum amount of development milestone payments per medicine over term of collaboration Maximum amount of development milestone payments per medicine over term of collaboration The maximum amount of regulatory milestone payments to be received for each medicine that achieves marketing approval over the term of the collaboration. Maximum amount of regulatory milestone payments per medicine over term of collaboration Maximum amount of regulatory milestone payments per medicine over term of collaboration The maximum amount of license fees to be received for each medicine that achieves marketing approval over the term of the collaboration. Maximum amount of license fees per medicine over term of collaboration Maximum amount of license fees per medicine over term of collaboration Tofersen (IONIS-SOD1Rx or BIIB067), or QALSODY, is an antisense medicine designed to inhibit the production of superoxide dismutase 1, or SOD1, which is a well understood genetic cause of familial amyotrophic lateral sclerosis, or ALS. QALSODY [Member] QALSODY [Member] The maximum amount of payments the Company is eligible to receive for each medicine that achieves marketing approval over the term of the collaboration. Maximum amount of payments receivable per medicine over term of collaboration Maximum amount of payments receivable per medicine over term of collaboration ION582 is an antisense investigational medicine that targets Ubiquitin Protein Ligase E3A-Antisense Transcript (UBE3A-ATS), which is a long non-coding ribonucleic acid (lncRNA). ION582 [Member] ION582 [Member] The cash premium paid on the purchase of the Company's common stock under the collaboration agreement. Premium paid on shares purchased Premium paid on shares purchased Research and development revenue from SPINRAZA (nusinersen). SPINRAZA Research and Development [Member] SPINRAZA R&D Revenue [Member] Collaborative agreement entered into with Biogen Inc. in December 2012 focused on developing and commercializing novel antisense drugs for up to three targets to treat neurological or neuromuscular diseases. Biogen Collaboration, 2012 Neurology [Member] 2012 Neurology [Member] Collaboration agreement entered into with Biogen Inc. in April 2018 to develop novel antisense drug candidates for a broad range of neurological diseases. Biogen Collaboration, 2018 Neurology [Member] 2018 Neurology [Member] Collaborative agreement entered into with Biogen Inc. in September 2013 focused on applying antisense technology to advance the treatment of neurodegenerative diseases. Biogen Collaboration, 2013 Neurology [Member] 2013 Neurology [Member] Collaboration agreement entered into with Biogen Inc. in January 2012 to develop and commercialize nusinersen for the treatment of spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality. Biogen Collaboration, Spinraza [Member] SPINRAZA [Member] Collaboration agreement entered into with Biogen Inc. in December 2017 to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy, or SMA. Biogen Collaboration, New Antisense Medicines for Treatment of SMA [Member] New Antisense Medicines for the Treatment of SMA [Member] ATTRv-PN is a debilitating disease that leads to peripheral nerve damage with motor disability within five years of diagnosis. ATTRv-PN [Member] ATTRv-PN [Member] Royalty percentage received on sales of a medicine in the United States by a collaboration partner under the collaboration agreement. Royalty percentage received on sales of medicine in United States Royalty percentage received on sales of medicine in U.S. The number of material components identified in the collaboration agreement under Accounting Standards Codification (ASC) 808, Collaborative Arrangements. Number of material components Number of material components Percentage of costs associated with the ongoing global Phase 3 development program paid by a collaboration partner under the collaboration agreement. Percentage of costs associated with ongoing global Phase 3 development program paid by Collaboration Partner Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca Collaboration agreements entered into with Novartis International AG (Novartis). Novartis Collaborations [Member] Novartis [Member] Collaboration agreement entered into with Novartis International AG (Novartis) in August 2023 for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease. Novartis Collaboration, Lp(a)-Driven Cardiovascular Disease [Member] Lp(a)-Driven Cardiovascular Disease [Member] Collaboration agreement entered into with Novartis International AG (Novartis) in January 2017 to develop and commercialize pelacarsen. Novartis Collaboration, Pelacarsen [Member] Pelacarsen [Member] The active pharmaceutical ingredient, or API, for Pelacarsen, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein Lp(a). Pelacarsen Active Pharmaceutical Ingredient [Member] Pelacarsen API [Member] The total amount of the premium received over the trading price of common stock at the time of purchase. Premium received on shares issued Premium received on shares issued The potential premium received if common stock was purchased in the future under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement. Potential premium received if common stock was purchased in future Potential premium received if common stock was purchased in the future Exclusive license agreement entered into with PTC Therapeutics in August 2018 to commercialize TEGSEDI and WAYLIVRA in Latin America and certain Caribbean countries. PTC Therapeutics Collaboration [Member] PTC Therapeutics [Member] Royalty percentage received on the net sales of each medicine from the collaboration partner under the collaboration agreement. Royalty percentage received on net sales of each medicine from collaboration partner Royalty percentage received on net sales of medicine The number of therapeutic programs with exclusive license rights under the collaboration agreement. Number of therapeutic programs The number of therapeutic targets granted by the partner under the collaboration agreement. Number of therapeutic targets granted by partner under collaboration agreement Number of therapeutic targets granted to Ionis The number of unnamed therapeutic targets granted by the partner under the collaboration agreement. Number of unnamed therapeutic targets granted by partner under collaboration agreement Number of unnamed therapeutic targets granted to Ionis Collaboration agreement entered into with Alnylam Pharmaceuticals, Inc. in March 2004 to develop and commercialize RNAi therapeutics. Alnylam Collaboration [Member] Alnylam [Member] The number of therapeutic targets granted to the partner under the collaboration agreement. Number of therapeutic targets granted to partner under collaboration agreement Number of therapeutic targets granted by Ionis Represents the cash outflow for payments made under the collaboration agreement for the reimbursement of support received in connection with the Company's Huntington's disease program. Payments made under collaboration agreement Payment of license fee Acquisition of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Investment in Equity Securities, FV-NI Equity investment Period after completion of initial public offering by an equity investee and restriction to sell equity holding in the investee, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lock up Agreement, Term of Trading Restriction Trading restriction period under lock up agreement Collaboration agreement entered into with Bicycle Therapeutics in December 2020, including an option to license Bicycle's peptide technology to potentially increase the delivery capabilities of the Company's Ligand Conjugated Antisense, or LICA, medicines. Bicycle Collaboration [Member] Bicycle License Agreement [Member] Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued commercial expenses, Current Commercial expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued clinical development expenses Clinical expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for in-licensing fees under collaboration agreements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued in-licensing fees, Current In-licensing expenses Physical assets used in the normal conduct of business and not intended for resale, excluding land. Examples include, but are not limited to, buildings, land and leasehold improvements, machinery and equipment, office equipment, and furniture and fixtures. Property, Plant and Equipment, Excluding Land [Member] Collaborative agreement entered into with Biogen Inc. in September 2013 focused on applying antisense technology to advance the treatment of neurodegenerative diseases. Biogen Collaboration, 2013 Strategic Neurology [Member] 2013 Strategic Neurology Collaboration with Biogen [Member] Revenue from the sale of other medicines commercially. Other [Member] Other Revenue [Member] Collaboration agreement entered into with Otsuka Pharmaceutical Co., Ltd. (Otsuka) in December 2023 to develop and commercialize donidalorsen, an investigational ligand-conjugated antisense (LICA) medicine designed to target the prekallikrein (PKK) pathway. Otsuka Collaboration, Donidalorsen [Member] Donidalorsen [Member] Research and development (R&D) services for donidalorsen, an investigational ligand-conjugated antisense (LICA) medicine designed to target the prekallikrein (PKK) pathway. Research and Development Services for Donidalorsen [Member] R&D Services for Donidalorsen [Member] License of donidalorsen, an investigational ligand-conjugated antisense (LICA) medicine designed to target the prekallikrein (PKK) pathway. License of Donidalorsen [Member] License of Donidalorsen [Member] Operations focused on the research, development and commercialization of RNA-targeted medicines to bring better futures to people with serious diseases. Ionis Operations [Member] Ionis Operations [Member] Expenses related to drug discovery research and advancing the Company's core technology. Drug Discovery Expenses Drug discovery Expenses related to drug development, including expenses for marketed medicines and those in Phase 3 development. Drug Development Expenses Drug development Expenses related to medical affairs for funding and coordinating investigator-sponsored trials, communicating scientific and clinical information to healthcare providers, medical professionals and patients, and managing publications. Medical Affairs Expenses Medical affairs Expenses related to manufacturing and development chemistry for providing drug supplies to drug development and our collaboration partners, including personnel costs, specialized chemicals for oligonucleotide manufacturing, validation batches to support regulatory approvals, laboratory supplies and outside services. Manufacturing and Development Chemistry Expenses Manufacturing and development chemistry Expenses related to research and development support such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of intellectual property, information technology costs, procurement costs and waste disposal costs. Research and Development Support Expenses R&D support